Levamisole and the New Era of Chemoimmunotherapy

References

• The Cancer Letter 1989–1989; 15(23)1–5; 48, 7
   Google Scholar
• The Cancer Letter 1990; 16(7)5–8
   Google Scholar
• Amery WK. 1 Review/commentary. The dosage regimen of levamisole in cancer: Is it related to efficacy and safety?. Int J Immunopharm 1983; 5(1)1–9
   PubMed Web of Science ®Google Scholar
• Chabner B, Sussman J, Wiernik P, et al. Combined biotherapy. A panel discussion. Proc New Directions and Combinations of Biotherapy. San Francisco, May 1989. Sem Oncol 1990; 17(1)38–41
   PubMedGoogle Scholar
• Greenspan EM. Is BCG an ‘orphan’ drug suffering from chemotherapists' overkill?. Cancer Invest 1986; 4(1)81–92
   PubMed Web of Science ®Google Scholar
• Baden ET, Davis TE, Crowley JJ, . Interim analysis of a trial of levamisole and 5-fluorouracil in metastatic colorectal carcinoma. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Excerpta Medica, Elsevier, North Holland, New York 1982; 231–236
   Google Scholar
• Laurie JA, Moertel CG, Fleming TR, et al. Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and 5-fluorouracil. J Clin Oncol 1989; 7: 1447–1456
   PubMed Web of Science ®Google Scholar
• Verbaeggen H, DeCree J, DeCock W, . Levamisole therapy in patients with colorectal cancer. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Excerpta Medica, North Holland, Elsevier, New York 1982; 225–229
   Google Scholar
• Sept., 1989, Update, NCI, National Institutes of Health
   Google Scholar
• Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352–358
   PubMed Web of Science ®Google Scholar
• Mayer RJ. Does adjuvant therapy work in colon cancer?. N Engl J Med 1990; 322: 399–401
   PubMed Web of Science ®Google Scholar
• Wadler S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2a in the treatment of colorectal carcinoma. Sem Oncol 1990; 17(1)16–21
   PubMed Web of Science ®Google Scholar
• Ansfield FJ, Klotz JH, Nealton TF, et al. A phase III study comparing the clinical utility of four regimens of 5-fluorouracil: A preliminary report. Cancer 1977; 39: 34–40
   PubMed Web of Science ®Google Scholar
• Focan C, Schyns-Mosen J, Focan-Henrard D. Levamisole or placebo after effective chemotherapy for remission and survival prolongation in advanced human solid tumors—a double-blind randomized trial. Corres Short Commun. 1988, 105–106
   Google Scholar
• Levy EM, Schmid K, Cooperband SR, Merluzzi VJ. Isolation and characterization of murine spleen cells responsive to levamisole. Clin Immunol Immunopathol 1978; 9: 47–54
   PubMedGoogle Scholar
• Jerry LM, Lewis MG, Cano P. Anergy, anti-antibodies and immune complex disease: a syndrome of disordered immune regulation in human cancer. Immunocancerology in Solid Tumors., M. Martin, L. Dione. Symposia Specialists, Miami 1976; 63–79
   Google Scholar
• Amergy WK. Cancer immunotherapy: some critical comments regarding immunological monitoring. Int J Immunopharm 1981; 3(4)339–348
   PubMed Web of Science ®Google Scholar
• Verhaegen H, De Cock W, De Cree J. The effects of azathioprine and levamisole on rosette-forming cells of healthy subjects and cancer patients. Clin Exp Immunol 1977; 29: 311–315
   PubMed Web of Science ®Google Scholar
• Nathanson SD, Zamfirescu PL, Portaro JK, et al. Acute effects of orally administered levamisole on random monocyte motility and chemotaxis in man. J Natl Cancer Inst 1978; 61: 301–306
   PubMed Web of Science ®Google Scholar
• Taylor SA, Currie GA. Monocyte maturation and prognosis in primary breast cancer. Br Med J 1979; 1: 1050
   PubMed Web of Science ®Google Scholar
• Amery WK. A hypothesis. The mechanism of action of levamisole: immune restoration through enhanced cell maturation. J Reticuloendothel Soc 1978; 24: 187–193
   PubMedGoogle Scholar
• De Cock W, De Cree J, Verhaegen H. Inhibition of the E-rosette formation of T-lymphocytes by aggregated human IgG and restoration by levamisole. Immunology 1978; 35: 223–227
   PubMed Web of Science ®Google Scholar
• Moroz C, Lahat N, Biniaminov M, Ramot B. Ferritin on the surface of lymphocytes in Hodgkin's disease patients. A possible blocking substance removed by levamisole. Clin Exp Immunol 1977; 29: 30–35
   PubMed Web of Science ®Google Scholar
• Nicholls EM, Lazer CE, Mitchell NR. Tumour immunity: what should be monitored and why?. Medikon 1978; 7: 5
   Google Scholar
• Del Giacco GS, Tognella S, Leone AL, et al. Interference of levamisole with inhibition of E-rosette formation by Hodgkin's disease and systemic lupus erythematous cytotoxic sera. Blood 1979; 53: 1002–1006
   PubMed Web of Science ®Google Scholar
• Amery WK, Gough DA. Levamisole and immunotherapy: Some theoretic and practical considerations and their relevance to human disease. Oncology 1981; 38: 168–181
   PubMed Web of Science ®Google Scholar
• Mussche RA, Kluyskens P. Prognosis of primarily treated localized laryngeal carcinoma ameliorated through levamisole treatment. A randomised pilot study. Oncology 1980; 37: 329–335
   PubMed Web of Science ®Google Scholar
• Amery WK, Cosemans J, Gooszen HC, . Four year results from double-blind study of adjuvant levamisole treatment in resectable lung cancer. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Elsevier, North Holland, New York 1982; 123–133
   Google Scholar
• Debois JM. Control of neoplasia by modulation of the immune system. Progress in Cancer Research and Therapy., MA. Chirigo. Raven Press, New York 1977; vol 2
   Google Scholar
• Han T, Dadey B, Nemoto T, Amery W. Monocyte-mediated suppression of T-lymphocyte proliferative response in breast and colorectal cancer patients = specific action of levamisole on suppressor monocytes. Int J Immunopharm 1981; 3(1)103–111
   PubMed Web of Science ®Google Scholar
• Serrou B, Caraux J, Thierry C, Goldstein A. Modulation of human helper and suppressor cell functions and autorosette forming cells (ARFC) in vitro by thymosin and levamisole. Procedeings of the Meteing on Immunological Aspects of Experimental and Clinical Cancer. Tel Aviv October 28-November 1, 1979
   Google Scholar
• Rosenthal M, Trabert U, Mueller W. The effect of levamisole on peripheral blood lymphocyte subpopulations in patients with rheumatoid arthritis and ankylosing spondylitis. Clin Exp Immun 1976; 25: 493–496
   PubMed Web of Science ®Google Scholar
• Babusikova O, Novotna L, Schnekova K, et al. T and B lymphocytes in malignant melanoma patients. Neoplasma 1976; 3: 635–644
   Google Scholar
• Tripodi D, Parks LC, Brugmans J. Drug-induced restoration of cutaneous delayed hypersensitivity in anergic patients with cancer. N Engl J Med 1973; 289: 354–357
   PubMed Web of Science ®Google Scholar
• Ramot B, Biniaminov M, Shoham CH, Rosenthal E. The effect of levamisole on E-rosette-forming cells in vivo and in vitro in Hodgkin's disease patients. N Engl J Med, 294: 809–811
   PubMed Web of Science ®Google Scholar
• Renoux G, Renoux M. Influence de l'administration de levamisole sur la reactivite des lymphocytes T de cancereux anvances. Nouv Press Med 1976; 5: 67–70
   PubMedGoogle Scholar
• Jerry LM, Shea M. Lymphocyte subpopulations in malignant melanoma. Clin Res 1977; 25: 710A
   Google Scholar
• Holmes EC, Golub SH. The effect of levamisole on cell-mediated immunity in patients with lung cancer. Immune Modulation and Control of Neoplasia by Adjuvant Therapy., MA. Chirigos. Raven Press, New York 1978; 107–118
   Google Scholar
• Groveman DS, Borden EC. In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma. J Biol Resp Modif 1983; 2: 167–174
   PubMedGoogle Scholar
• Verhaegen H, De Cree J, De Beukelaar A, et al. The immunological evaluation of levamisole treatment in cancer patients. Postgrad Med J 1978; 54: 799–805
   Web of Science ®Google Scholar
• Child JA, Martin S, Cawley JC, Ghoneim ATM. Defective microbicidal function of neutrophils in haematological malignancies and lymphomas: correction by levamisole in vitro. Biomedicine 1978; 29: 159–161
   PubMedGoogle Scholar
• Urist MM, Boddie AW, Townsend CM, Holmes EC. In vitro evidence for increased cellular immunity to lung cancer antigen during levamisole immunotherapy. J Thorac Cardiovasc Surg 1977; 73: 189–194
   PubMed Web of Science ®Google Scholar
• Jerry LM, Lewis MG, Shibata HR, . Combination immunotherapy with levamisole, BCG and tumor vaccines: toward a rationale. Immune Modulation and Control of Neoplasia by Adjuvant Therapy., MA. Chirigos, et al. Raven Press, New York 1978; 147–156
   Google Scholar
• Cochran AJ, Spilg WGS, Mackie RM, Thomas CE. Postoperative depression of tumor-directed cell-mediated immunity in patients with malignant disease. Br Med J 1972; 4: 67–70
   PubMed Web of Science ®Google Scholar
• Windle R, Bell PRF, Shaw D. Five year results of a randomized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 469–572
   PubMedGoogle Scholar
• Miwa H, Kawai T, Nakahara H, Orita K. Decrease in cell-mediated immunity by surgical intervention and its prevention by levamisole. Int J Immunopharmac 1980; 2: 31–36
   Web of Science ®Google Scholar
• Gropp C, Havemann K. Cellular immune reactions in patients with bronchogenic carcinoma before and after radio, chemo- and immunotherapy. Z Immunitaetsforsch 1977; 153: 236–247
   PubMedGoogle Scholar
• Stephens EJW, Wood HF, Mason B. Levamisole as adjuvant to cyclic chemotherapy in breast cancer. Rec Res Cancer Res 1979; 68: 139–145
   Google Scholar
• Schreml W, Lohrmann HP. No effects of levamisole on cytotoxic drug-induced changes of human granulopoiesis. Blut 1979; 38: 331–336
   PubMedGoogle Scholar
• Sone S, Yata K, Tsubura E. Rebound phenomenon of phytohemagglutinin skin reactivity in cases of leukemia and malignant lymphoma after chemotherapy. Gann 1977; 68: 483–490
   PubMedGoogle Scholar
• Anderson R, Oosthuizen R, Theron A, Van Rensburg J. The in vitro evaluation of certain neutrophil and lymhocyte functions following the ingesting of on 150 mg oral dose of levamisole: assessment of the extent and duration of stimulation of neutrophil chemotaxis, protein iodination and lymphocyte transformation. Clin Exp Immun 1979; 35: 478–483
   PubMed Web of Science ®Google Scholar
• Rojas AF, Mickiewicz E, Feierstein JN, et al. Levamisole in advanced human breast cancer. Lancet i 1976; 211–215
   PubMed Web of Science ®Google Scholar
• De Carli HO, Llargues JM. La immunoterapia del cancer mediante levamisole, control immunologico del paciente post quirivigico y su seguimiento grafico. Rev Esp Oncol 1981
   Google Scholar
• Cove-Smith JR, Kabler P, Pownall R, Knapp MS. Circadian variation in an immune response in man. Br Med J 1978; 3: 253–254
   Google Scholar
• Cabanillas F, Rodriguez V, Hersh EM, et al. Chemoimmunotherapy of advanced non-Hodgkin's lymphoma (NHL) with CHOP-Bleo + levamisole (Abstr). Proc Am Assoc Cancer Res Am Soc Clin Oncol 1977; 18: 328
   Web of Science ®Google Scholar
• Pulay TA, Csomor S. Effect of levamisole treatment on immunological parameters and the early course of cervical cancer. Neoplasma 1982; 29(1)81–86
   PubMed Web of Science ®Google Scholar
• Klefstrom P, Holsti P, Grohn P, Heinonen E. Combination of levamisole immunotherapy with conventional treatments in breast cancer. Immunotherapy of Human Cancer., WD. Terry, S. Rosenberg. Elsevier, North Holland, New York 1982; 187–194
   Google Scholar
• Schreml W, Betzler M, Long M, et al. Adjuvant intermittent chemoimmunotherapy of breast cancer. A prospective study. Eur J Cancer 1980; 1: 165–168
   PubMedGoogle Scholar
• Klefstrom P. Combination of levamisole immunotherapy and polychemotherapy in advanced breast cancer. Cancer Treat Rep 1980; 64: 65–72
   PubMedGoogle Scholar
• Shiraki S, Mori H, Kadomoto N, et al. Adjuvant immunotherapy of carcinoma colli with levamisole prevention of immunological depression following surgical therapy and radiotherapy. Int J Immunopharmacol 1982; 4(1)73–80
   PubMed Web of Science ®Google Scholar
• Olivari AJ, Glait HM, Guardo A, et al. Levamisole in squamous cell carcinoma of the head and neck. Cancer Treat Rep 1979; 63: 983–990
   PubMedGoogle Scholar
• Wanebo HJ, Hilal EY, Strong EW, et al. Randomized trial of levamisole in patients with squamous cancer of head and neck. Proc AACR/ASCO 1978; 19: C–189
   Google Scholar
• Jones S, Grozea PN, Miller TP, et al. Chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone alone or with levamisole or with levamisole plus BCG for malignant lymphoma. A SWOG study. J Clin Oncol 1985; 3(10)1318–1324
   PubMed Web of Science ®Google Scholar
• Pines A. BCG plus levamisole following irradiation of advanced squamous bronchial carcinoma. Int J Radiat Oncol Biol Phys 1980; 6: 1041–1042
   PubMed Web of Science ®Google Scholar
• Quirt I, Shelley W, Bodwitha A, et al. Adjuvant levamisole improves SV and DFS in patients with poor prognosis in malignant melanoma. Proc Am Soc Clin Oncol 1986; 5: 130
   Google Scholar
• Wright PW, Hill LD, Peterson AV, . Adjuvant immunotherapy with intrapleural BCG and levamisole in patients with resected, non-small cell lung cancer. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Elsevier, North Holland, New York 1982; 105–110
   Google Scholar
• Forastiere AA, Hakes TB, Tallos P, et al. CMF+levamisole breast adjuvant chemotherapy: analysis of results after 3.5 years. Cancer Res 1980; 21: 402
   Web of Science ®Google Scholar
• Klefstrom P, Holsti P, Grohn P, et al. Levamisole in the treatment of stage II breast cancer. Cancer 1985; 55: 2753–2757
   PubMed Web of Science ®Google Scholar
• Treurniet-Donker AD, Meiscke de Jongh ML, van Puttens WLJ. Levamisole as adjuvant immunotherapy in breast cancer. Cancer 1987; 59: 1590–1593
   PubMed Web of Science ®Google Scholar
• Danish Breast Cancer Cooperative Group: Increased breast cancer recurrence rate after adjuvant therapy with levamisole. Lancet 1980; 2: 824–827
   PubMed Web of Science ®Google Scholar
• Olivari J, Galit HM, Varela OA, Feierstein JN. Six years' follow-up in levamisole treated stage III breast cancer patients. Cancer Res 1980; 21: 362
   Web of Science ®Google Scholar
• Samal BA, Foukes MA, McDonald B. Levamisole probably shortens response and survival in CMFP-maintained advanced breast cancer patients. A Southwest Oncology Group Study. Proc ASCO (Abstr C-495) 1984; 3: 126
   Google Scholar
• Brincker H, Mouridsen HT, Anderson KW, et al. Increased recurrence rate following adjuvant therapy of breast cancer with levamisole. A preliminary report. Lancet 1980; 2: 824–827
   PubMed Web of Science ®Google Scholar
• Galvez CA. October, 1978, 3-drug combination chemotherapy with ADR/CTX/ 5-FU plus immunotherapy with levamisole vs 3-drug combination chemotherapy with ADR/CTX/5-FU plus immunotherapy with BCG for stage IV breast carcinoma. 12th International Cancer Congress, Workshop 28, Buenos Aires
   Google Scholar
• Hortobagyi GN, Gutterman JU, Blumenschein GR, et al. Combined chemoimmunotherapy for advanced breast cancer. A comparison of BCG and levamisole. Cancer 1979; 43: 1112–1122
   PubMed Web of Science ®Google Scholar
• Naglas M, Kmetec A, Cas B, Plesnicar S. Controlled clinical trial of chemoimmunotherapy with levamisole in breast cancer stage IV. Zdrav Vestn 1980; 49: 641–643
   Google Scholar
• Paterson AHG, Nutting M, Takats L, et al. Chemoimmunotherapy with levamisole in metastatic breast carcinoma: a controlled clinical trial. Cancer Clin Trials 1980; 3: 5–10
   PubMedGoogle Scholar
• Rojas AF, Feierstein AF, Glait HM, Olivari AJ. Levamisole action in breast cancer stage III. Immunotherapy for Cancer: Present Status of Trials in Man., WD. Terry, D. Windhorst. Raven Press, New York 1978; 635–645
   Google Scholar
• Chlebowski RT, Nystrom S, Reynolds R, et al. Long-term survival following levamisole or placebo adjuvant treatment of colorectal cancer. Oncology 1988; 45: 141–143
   PubMed Web of Science ®Google Scholar
• Bancerwicz J, Calman KC, MacPherson SG, et al. Adjuvant chemotherapy and immunotherapy for colorectal cancer: preliminary communication. JR Soc Med 1980; 73: 197–199
   PubMed Web of Science ®Google Scholar
• Bedikian Ay, Valdivieso M, Mavligit GM, et al. Sequential chemoimmunoftherapy of colorectal cancer. Evaluation of methotrexate, Baker's antifol and levamisole. Cancer 1978; 42: 2169–2176
   PubMed Web of Science ®Google Scholar
• Miwa H, Ono F, Mimura H, Orita K. Effect of immunochemotherapy using levamisole on colon cancer. Presentation at the 15th Annual Meteing of the Japanese Society of Surgery of Digestive System. Fokuoka February, 1980; 28–29
   Google Scholar
• Araaud J, Buyse M, Nordinger B, et al. Adjuvant therapy of poor prognosis colon cancer with levamisole: results of an EORTC double-blind randomized clinical trial. Br J Surg 1989; 76: 284–289
   PubMed Web of Science ®Google Scholar
• Chahinian AP, Goldberg JA, Holland JF, et al. Chemotherapy versus chemoimmunotherapy with levamisole orCorynebacterium parvumin advanced lung cancer. Cancer Treat Rep 1982; 66: 1291–1297
   PubMedGoogle Scholar
• VanHoutte P, Bondue H, Rocmans P, et al. Adjuvant immunotherapy by levamisole in resectable lung cancer. Eur J Cancer 1980; 16: 1597–1601
   PubMed Web of Science ®Google Scholar
• Anthony HM, Meams AJ, Masono MK, et al. Levamisole and surgery in bronchial carcinoma patients. Thorax 1979; 34: 4–12
   PubMed Web of Science ®Google Scholar
• Herskovic A, Bauer M, Seydel HG, et al. Postoperative thoracic irradiation with or without levamisole in non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1988; 14: 37–42
   PubMed Web of Science ®Google Scholar
• Fox RM, Woods RL, Tattersall MHN, Basten A. A randomized study of adjuvant immunotherapy with levamisole andC. parvumin operable non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1980; 6: 1043–1045
   PubMed Web of Science ®Google Scholar
• Okaysu T, Takeoka T, Moriyama Y, et al. Immunochemotherapy with levamisole in patients with primary lung cancer. Gan Kagaku-Royoho 1980; 7: 1479–1484
   Google Scholar
• Chahinian P, Holland JF, Teirstein A, et al. Comparison of the efficacy of MACC, MACC plusC. parvumand MACC plus levamisole in the treatment of primary lung cancer. Janssen Research Product Information Service. Clin Res Rep 1980; 113
   Google Scholar
• Spittler LE, Sagebeil R, Allen R, . Levamisole in the treatment of melanoma. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Elsevier, Holland, New York 1982; 289–297
   Google Scholar
• Spittler LE, Sagebiel R. A randomized trial of levamisole versus placebo as adjuvant therapy of malignant melanoma. N Engl J Med 1980; 303: 1143–1147
   PubMed Web of Science ®Google Scholar
• Hall SW, Benjamin RS, Lewinski U, Mavligit G. Actinomycin-D, levamisole chemoimmunotherapy of refractory malignant melanoma. Cancer 1975; 43: 1195–1200
   Google Scholar
• Pinsky CM, Hilal EY, Wanebo HJ, . Randomized trial of levamisole in patients with squamous cell carcinoma of head and neck: preliminary results. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg, et al. Elsevier, North Holland, New York 1982; 353–359
   Google Scholar
• Focan C. Agranulocytosis and tumoural facilitation induced by levamisole in a case of IgG multiple myeloma. Cancer Immunol Immunother 1979; 6: 263–264
   Web of Science ®Google Scholar
• Salmon SE, Haut A, Bonnet JD, et al. Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: Southwest Oncology Group Study. J Clin Oncol 1982; 1: 453
   Web of Science ®Google Scholar
• Khoo SK, Whitaker SV, Jones ISC, Thomas DA. Levamisole as adjuvant to chemotherapy of ovarian cancer. Cancer 1984; 54: 986–990
   PubMed Web of Science ®Google Scholar
• Pavlovsky S, Sackman MF, Garay G, et al. Chemoimmunotherapy with levamisole in acute lymphoblastic leukemia. Cancer 1981; 48: 1500–1507
   PubMed Web of Science ®Google Scholar
• Pavlovsky S. Levamisole therapy during maintenance of remission in patients with acute lymphoblastic leukemia. Immunotherapy of Human Cancer., WD. Terry, SA. Rosenberg. Elsevier, North Holland, New York 1982; 47–54
   Google Scholar
• Van Sloten K, Wiernik PH, Schiffer CA. Evaluation of levamisole as an adjuvant to chemotherapy for treatment of ANLL. Cancer 1983; 51: 1576–1580
   PubMed Web of Science ®Google Scholar
• Clinical Cancer Letter March, 1990; 13(3)
   Google Scholar